Pharmacokinetics: Drug Absorption, Distribution, Metabolism, and Excretion (ADME)

Pharmacokinetics describes how the body affects a drug after administration, encompassing absorption, distribution, metabolism, and excretion (ADME). Understanding these processes is crucial for determining appropriate drug dosages and predicting therapeutic outcomes, as they govern drug concentration at the site of action over time.

Absorption is the process by which a drug moves from the site of administration into the systemic circulation. This process is influenced by several factors including the route of administration (oral, intravenous, intramuscular, subcutaneous, transdermal), the drug's formulation (e.g., tablet, capsule, solution), the drug's physiochemical properties (e.g., lipophilicity, ionization), and physiological factors such as gastric emptying, intestinal motility, and blood flow to the absorption site. Oral bioavailability is significantly affected by first-pass metabolism in the liver.

Distribution refers to the reversible transfer of a drug from one location to another within the body. Once a drug is absorbed into the bloodstream, it is distributed to various tissues and organs. Factors affecting distribution include blood flow, tissue permeability, binding to plasma proteins (e.g., albumin), binding to tissue components, and the drug's lipid solubility. Only unbound (free) drug can exert its pharmacological effect. The volume of distribution (Vd) is a theoretical volume representing the extent to which a drug is distributed throughout the body.

Metabolism, also known as biotransformation, is the process by which the body chemically alters a drug. The liver is the primary site of drug metabolism, although metabolism can also occur in other tissues such as the kidneys, intestines, and lungs. Metabolism typically involves two phases: Phase I reactions (oxidation, reduction, hydrolysis), often involving cytochrome P450 enzymes, which introduce or expose a functional group on the drug molecule; and Phase II reactions (conjugation), which involve the attachment of a polar molecule (e.g., glucuronic acid, sulfate) to the drug, making it more water-soluble and easier to excrete. Prodrugs are inactive compounds that are metabolized into active drugs.

Excretion is the process by which drugs and their metabolites are eliminated from the body. The kidneys are the primary organs of excretion, eliminating drugs via glomerular filtration, tubular secretion, and tubular reabsorption. Other routes of excretion include bile (followed by fecal elimination), lungs (for volatile anesthetics), sweat, and breast milk. Renal clearance is a measure of the kidney's ability to eliminate a drug from the body. Factors affecting renal excretion include renal blood flow, glomerular filtration rate, and tubular function.

Bioavailability refers to the fraction of an administered dose of unchanged drug that reaches the systemic circulation. Intravenous administration results in 100% bioavailability. Oral bioavailability is often less than 100% due to incomplete absorption and first-pass metabolism. Bioavailability is an important parameter in determining the appropriate dose of a drug for a given route of administration. It is calculated by comparing the area under the plasma concentration-time curve (AUC) for a drug given by a particular route to the AUC for the same drug given intravenously.

Drug interactions can significantly affect ADME processes, leading to altered drug concentrations and potential therapeutic or toxic effects. Enzyme induction increases the activity of metabolizing enzymes, leading to decreased drug concentrations. Enzyme inhibition decreases the activity of metabolizing enzymes, leading to increased drug concentrations. Drug interactions can also affect absorption (e.g., chelation), distribution (e.g., displacement from plasma proteins), and excretion (e.g., competition for renal transporters).

Individual patient factors play a critical role in determining pharmacokinetic parameters. Age, genetics, disease state (e.g., renal or hepatic impairment), body weight, and concurrent medications can all influence ADME processes. Pediatric and geriatric patients often exhibit altered drug metabolism and excretion. Genetic polymorphisms in drug-metabolizing enzymes (e.g., CYP2D6) can lead to interindividual variability in drug response. Disease states can impair organ function and affect drug clearance. Understanding these factors is essential for optimizing drug therapy and minimizing adverse effects.

Browse public study notes